Filtered By:
Condition: Heart Failure
Drug: Insulin

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 323 results found since Jan 2013.

Clinical implications of cardiovascular outcome trials in type  2 diabetes.
Clinical implications of cardiovascular outcome trials in type 2 diabetes. Herz. 2019 Feb 25;: Authors: Mellbin LG, Wang A, Rydén L Abstract Cardiovascular disease (CVD) is the main reason for premature death in patients with type 2 diabetes. Hyperglycemia, the hallmark of diabetes, has long been considered the link between diabetes and CVD, and many trials focused on preventing CVD manifestations by means of tight glucose control. However, diabetes is a multifactorial disease in which, e. g., insulin resistance, endothelial dysfunction, and factors such as hypertension and dyslipidemia contrib...
Source: Herz - February 27, 2019 Category: Cardiology Tags: Herz Source Type: research

The incidence rate of diabetes mellitus (type II) and its related risk factors: A 10-year longitudinal study of Yazd Healthy Heart Cohort (YHHC), Iran
ConclusionIn the present study, Age, family history of DM, abdominal obesity, high triglycerides, and high uric acid are the most important risk factors for diabetes.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - February 27, 2019 Category: Endocrinology Source Type: research

Incidence rate of diabetes mellitus (type II) and its related risk factors: A 10-year longitudinal study of Yazd Healthy Heart Cohort (YHHC), Iran
ConclusionIn the present study, Age, family history of DM, abdominal obesity, high triglycerides and high uric acid are the most important risk factors for diabetes.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - February 6, 2019 Category: Endocrinology Source Type: research

The morphofunctional features of platelets against the background of metabolic syndrome in patients with generalized marginal periodontitis
Conclusion: The presented data provide strong evidence for changes in the morphofunctional state of peripheral blood platelets in patients with generalized marginal periodontitis of mild and moderate degree against the background of metabolic syndrome.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - December 7, 2018 Category: Endocrinology Source Type: research

Chronic kidney disease among US adults with type 2 diabetes and cardiovascular diseases: A national estimate of prevalence by KDIGO 2012 classification
ConclusionsThis study confirms the high prevalence of CKD in patients with multiple comorbidities: T2D and CVD. It also provides estimates of the prevalence of CKD categories based on KDIGO 2012 classification for US adults with T2D.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - November 3, 2018 Category: Endocrinology Source Type: research

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
Abstract Patients with type 2 diabetes mellitus (T2DM) exhibit an increased risk for cardiovascular (CV) events. Hyperglycemia itself contributes to the pathogenesis of atherosclerosis and heart failure (HF) in these patients, but glucose-lowering strategies studied to date have had little or no impact on reducing CV risk, especially in patients with a long duration of T2DM and prevalent CV disease (CVD). Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the new class of glucose-lowering medications that increase urinary glucose excretion, thus improving glycemic control, independent of insulin. The recently p...
Source: Indian Heart J - November 1, 2018 Category: Cardiology Authors: Pancholia AK Tags: Indian Heart J Source Type: research

10 Ways to Keep Your Heart Healthy
No one ever had fun visiting the cardiologist. ­Regardless of how good the doc might be, it’s always a little scary thinking about the health of something as fundamental as the heart. But there are ways to take greater control—to ensure that your own heart health is the best it can be—even if you have a family history of cardiovascular disease. Although 50% of cardiovascular-disease risk is genetic, the other 50% can be modified by how you live your life, according to Dr. Eugenia Gianos, director of Women’s Heart Health at Lenox Hill Hospital in New York City. “This means you can greatly ...
Source: TIME: Health - October 17, 2018 Category: Consumer Health News Authors: Lisa Lombardi and Jamie Ducharme Tags: Uncategorized Baby Boomer Health heart health Source Type: news

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
Publication date: Available online 1 September 2018Source: Indian Heart JournalAuthor(s): A.K. PancholiaAbstractPatients with type 2 diabetes mellitus (T2DM) exhibit an increased risk for cardiovascular (CV) events. Hyperglycemia itself contributes to the pathogenesis of atherosclerosis and heart failure (HF) in these patients, but glucose-lowering strategies studied to date have had little or no impact on reducing CV risk, especially in patients with a long duration of T2DM and prevalent CV disease (CVD). Sodium glucose cotransporter-2 (SGLT2)-inhibitors are the new class of glucose lowering medications that increase urin...
Source: Indian Heart Journal - September 1, 2018 Category: Cardiology Source Type: research

Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary.
Authors: Raskin P, Cincotta AH Abstract An extended series of studies indicate that endogenous phase shifts in circadian neuronal input signaling to the biological clock system centered within the hypothalamic suprachiasmatic nucleus (SCN) facilitates shifts in metabolic status. In particular, a diminution of the circadian peak in dopaminergic input to the peri-SCN facilitates the onset of fattening, insulin resistance and glucose intolerance while reversal of low circadian peak dopaminergic activity to the peri-SCN via direct timed dopamine administration to this area normalizes the obese, insulin resistant, gluco...
Source: Expert Review of Endocrinology and Metabolism - August 2, 2018 Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research

Current Strategies and Drug Targets in the Management of Type 2 Diabetes Mellitus.
CONCLUSION: This review discusses the strategies and future perspectives in the management of type 2 diabetes mellitus particularly antidiabetic agents which are helpful for the betterment of diabetic patients. PMID: 30051787 [PubMed - as supplied by publisher]
Source: Current Drug Targets - July 27, 2018 Category: Drugs & Pharmacology Authors: Kaur P, Mittal A, Nayak SK, Vyas M, Mishra V, Khatik GL Tags: Curr Drug Targets Source Type: research

Uric acid and cardiovascular disease
Publication date: September 2018Source: Clinica Chimica Acta, Volume 484Author(s): Gjin NdrepepaAbstractUric acid (UA) is an end product of purine metabolism in humans and great apes. UA acts as an antioxidant and it accounts for 50% of the total antioxidant capacity of biological fluids in humans. When present in cytoplasm of the cells or in acidic/hydrophobic milieu in atherosclerotic plaques, UA converts into a pro-oxidant agent and promotes oxidative stress and through this mechanism participates in the pathophysiology of human disease including cardiovascular disease (CVD). Most epidemiological studies but not all of ...
Source: Clinica Chimica Acta - July 11, 2018 Category: Laboratory Medicine Source Type: research

Long-term risk of rosiglitazone on cardiovascular events: a systematic review and meta-analysis.
Abstract Rosiglitazone has been proposed as a treatment strategy for type 2 diabetes mellitus (T2DM), could provide robust glucose-lowering capability with risk of cardiovascular events. We thus did a systematic review and meta-analysis of controlled trials to assess the effect of this treatment on glycaemic control, cardiovascular events in patients with T2DM. We systematically search PubMed, Embase and Cochrane Central Register of Controlled Trials comparing rosiglitazone to other anti-diabetic treatments. These studies included randomized controlled trials (RCTs), cohort studies, and case-control studies that h...
Source: Endokrynologia Polska - June 28, 2018 Category: Endocrinology Authors: Cheng D, Gao H, Li W Tags: Endokrynol Pol Source Type: research

Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone.
Conclusions -In IRIS, with surveillance and dose adjustments, pioglitazone did not increase risk of HF, and conferred net cardiovascular benefit in patients with insulin resistance and cerebrovascular disease. The risk of HF with pioglitazone was not modified by baseline HF risk. The IRIS experience may be instructive for maximizing the net benefit of this therapy. Clinical Trial Registration -URL: www.clinicaltrials.gov Unique identifier: NCT00091949. PMID: 29934374 [PubMed - as supplied by publisher]
Source: Circulation - June 22, 2018 Category: Cardiology Authors: Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz E, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN, IRIS Investigators Tags: Circulation Source Type: research

Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints.
CONCLUSION: The combination of metformin with SGLT2i, GLP-1 RA, and a potent statin, in high CVD risk patients with DM, is expected to substantially reduce CVD mortality and morbidity, improving the quality of life of patients with DM at the same time. Prospective studies are needed to confirm this finding. PMID: 29865997 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 3, 2018 Category: Drugs & Pharmacology Authors: Doumas M, Imprialos Κ, Stavropoulos K, Reklou A, Sachinidis A, Athyros VG Tags: Curr Pharm Des Source Type: research